作为治疗性宿主点,FABP4可以控制SARS-CoV-2感染
Hatoon Baazim1, Emre Koyuncu2, Gürol Tuncman1
1Sabri Ülker Center for Metabolic Research, Department of Molecular Metabolism, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
EMBO molecular medicine
|January 22, 2025
概括
脂肪酸结合蛋白4 (FABP4) 通过促进SARS-CoV-2复制来驱动严重的COVID-19. 抑制FABP4可降低病毒载量和肺损伤,提供一种潜在的治疗策略.
科学领域:
- 传染性疾病传染性疾病.
- 宿主-病原体相互作用
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 主体代谢健康显著影响传染病的严重程度.
- 肥胖和衰老是包括COVID-19在内的严重呼吸道感染的危险因素,但机制尚不清楚.
- 脂肪酸结合蛋白4 (FABP4) 与代谢功能障碍和炎症有关.
研究的目的:
- 调查FABP4在SARS-CoV-2病变发生中的作用.
- 探索FABP4作为COVID-19的潜在治疗点.
主要方法:
- 评估了FABP4表达和与COVID-19严重程度的相关性.
- 在细胞培养模型 (脂肪细胞,呼吸道上皮细胞) 中利用了FABP4的遗传和药理抑制.
- 在SARS-CoV-2感染的仓鼠模型中评估了FABP4抑制剂的有效性.
主要成果:
- FABP4表达与COVID-19疾病严重程度有很强的相关性.
- FABP4功能的丧失减少了SARS-CoV-2的复制和病毒器官的形成.
- 在子中抑制FABP4降低了肺病毒标位,肺损伤和原沉积.
结论:
- FABP4是调节SARS-CoV-2病变的关键宿主因子.
- 准FABP4代表了对抗冠状病毒感染的有希望的治疗策略.
- 主体代谢途径是控制病毒复制和疾病进展的关键目标.
相关概念视频
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
01:30Inhibitors of Viral Protein Synthesis
58
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
58